ID   KK
AC   CVCL_F844
DR   CGH-DB; 328-2
DR   Cosmic; 931361
DR   Cosmic; 1223313
DR   Cosmic; 1328072
DR   Cosmic; 1434897
DR   Cosmic; 2074242
DR   Cosmic; 2482702
DR   GEO; GSM416676
DR   GEO; GSM659379
DR   Wikidata; Q54899964
RX   PubMed=7844449;
RX   PubMed=8148309;
RX   PubMed=8375936;
RX   PubMed=15677628;
RX   PubMed=17671176;
RX   PubMed=20081105;
RX   PubMed=28196595;
RX   PubMed=30485824;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: ~4 days (Note=At 70th passage) (PubMed=8148309); 31 hours (PubMed=8375936).
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,11
ST   D16S539: 11,12
ST   D21S11: 30,31.2
ST   D5S818: 10,11
ST   D7S820: 10,11
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 14,17
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 29-06-23; Version: 16
//
RX   PubMed=7844449;
RA   Ishii K., Kita T., Kudo K., Hisano A., Hirata J., Imaizumi E.,
RA   Tode T., Kikuchi Y., Nagata I.;
RT   "Circumvention of cisplatin resistant ovarian cancer cells by
RT   antiestrogens.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 47:19-26(1995).
//
RX   PubMed=8148309;
RA   Sasa H., Ishii K., Hirata J., Kikuchi Y., Nagata I., Kawai T.,
RA   Senoo A., Sugita M., Sugishita T., Tenjin Y.;
RT   "Establishment and characterization of a CA125-producing human ovarian
RT   clear cell carcinoma cell line.";
RL   Hum. Cell 6:279-286(1993).
//
RX   PubMed=8375936; DOI=10.1002/ijc.2910550332;
RA   Hirata J., Kikuchi Y., Kita T., Imaizumi E., Tode T., Ishii K.,
RA   Kudoh K., Nagata I.;
RT   "Modulation of sensitivity of human ovarian cancer cells to
RT   cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate
RT   and D,L-buthionine-S,R-sulphoximine.";
RL   Int. J. Cancer 55:521-527(1993).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//
RX   PubMed=20081105; DOI=10.1210/me.2009-0295;
RA   Nagaraja A.K., Creighton C.J., Yu Z.-F., Zhu H.-F., Gunaratne P.H.,
RA   Reid J.G., Olokpa E., Itamochi H., Ueno N.T., Hawkins S.M.,
RA   Anderson M.L., Matzuk M.M.;
RT   "A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.";
RL   Mol. Endocrinol. 24:447-463(2010).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//